Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.56 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrolipoic Acid SCHEMBL618576 | 1.00 | FOLH1 (0.56) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL19773 | 1.00 | FOLH1 (0.56) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL1115003 | 1.00 | FOLH1 (0.56) | FOLH1GSTK1ENPEPLMNAANPEP | |
| SCHEMBL6805309 | 0.98 | GSTK1 (0.57) | FOLH1GSTK1ENPEPLMNAANPEP | |
| SCHEMBL21611884 | 0.98 | GSTK1 (0.57) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL2582098 | 0.98 | FOLH1 (0.54) | FOLH1GSTK1ENPEPLMNAANPEP | |
| SCHEMBL6809842 | 0.98 | GSTK1 (0.57) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL2578740 | 0.98 | FOLH1 (0.54) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL19359055 | 0.98 | FOLH1 (0.54) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL4761911 | 0.96 | FOLH1 (0.52) | FOLH1GSTK1ENPEPLMNAANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119875122-B | Hyperbranched polymer, nano preparation, and preparation methods and applications thereof | 中国海洋大学 | 2026-05-12 | — | — | CN | claimed |
| EP-3965823-B1 | USE OF GOLD NANOCLUSTERS IN TREATING HYPERCHOLESTEROLEMIA OR HYPERCHOLESTEROLEMIA-ASSOCIATED DISEASES | GOLDRED NANOBIOTECH CO LTD (TW) | 2026-03-11 | — | — | EP | claimed |
| US-20250207029-A1 | Luminescent Quantum Dot Thiol-yne Nanocomposites With Tailorable Optical, Thermal and Mechanical Properties | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2025-06-26 | — | — | US | claimed |
| EP-4561551-A1 | METHODS AND COMPOUNDS FOR TREATING ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, SEPSIS, AND POST-SEPSIS SYNDROME | Redox Bioscience LLC (US) | 2025-06-04 | — | — | EP | claimed |
| CN-120055254-A | Near infrared silver nanocluster, preparation method, application and experimental method | 重庆科技大学 | 2025-05-30 | — | — | CN | claimed |
| CN-119875122-A | Hyperbranched polymer, nano preparation, and preparation methods and applications thereof | 中国海洋大学 | 2025-04-25 | — | — | CN | claimed |
| CN-119744164-A | Odor and colorant stable compositions | 西姆莱斯股份公司 | 2025-04-01 | — | — | CN | claimed |
| CN-116102532-B | Method for recovering lipoic acid from lipoic acid crystallization mother liquor | 国药集团威奇达药业有限公司 | 2025-03-18 | — | — | CN | claimed |
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2025-02-27 | — | — | US | claimed |
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-20060045896-A1 | Topical compositions comprising benfotiamine and pyridoxamine | TRACIE MARTYN INTERNATIONAL, LLC | 2006-03-02 | — | — | US | claimed |
| US-6906210-B2 | Method for producing lipoic acid and dihydrolipoic acid | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-14 | — | — | US | claimed |
| EP-1374865-B1 | Use of R,S-(+/-)-alpha-lipoic acid, R(+)-alpha-lipoic acid or S-(-)-alpha-lipoic acid in reduced or oxidised form for the treatment of hearing disorders | VIATRIS GMBH (DE) | 2005-06-08 | — | — | EP | claimed |
| US-20050101669-A1 | Process for the preparation of lipoic acid and dihydrolipoic acid | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | US | claimed |
| US-20040044227-A1 | Method for producing lipoic acid and dihydrolipoic acid | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-04 | — | — | US | claimed |
| US-6284787-B1 | Use of R-(+)-α-lipoic acid, R-(−)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-09-04 | — | — | US | claimed |
| EP-0659408-B1 | Use of R(+)alpha-lipoic acid, R-(-)dihydrolipoic and metabolites for the treatment of diabetes mellitus and its resulting disorders | ASTA MEDICA AG (DE) | 2001-08-01 | — | — | EP | claimed |
| US-6117899-A | Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as its sequelae | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2000-09-12 | — | — | US | claimed |
| US-5948810-A | Use of R-(+)-α-lipoic acid, R-(-)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-09-07 | — | — | US | claimed |
| US-5693664-A | TREATING INSULIN RESISTANCE | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101669-A1 | Process for the preparation of lipoic acid and dihydrolipoic acid | ACSL3, ACSL6, ADSL | FOLH1 2872/4885GSTK1 1190/4885ENPEP 2898/4885 |
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | FOLH1 6/4885GSTK1 3347/4885ENPEP 136/4885 |
| US-20060045896-A1 | Topical compositions comprising benfotiamine and pyridoxamine | AGER, LPO, LOX | FOLH1 3004/4885GSTK1 2176/4885ENPEP 1298/4885 |
| US-20040044227-A1 | Method for producing lipoic acid and dihydrolipoic acid | LIPA, ACSL3, ACSL6 | FOLH1 3507/4885GSTK1 1266/4885ENPEP 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.